SJT Molecular Research is a Spanish Biotech Company focused on the discovery and development of a family of novel, oral, small molecules for the treatment of NASH, obesity, hyperlipidemia, hypertension and type 2 diabetes. SJT was born from the merger of several Spanish companies with over 20 years of experience in research and development in biotechnology. SJT Molecular's main asset has been the discovery of a family of molecules for the treatment of the metabolic syndrome, including obesity, hepatic steatosis, NASH, diabetes, hypercholesterolemia and hypertension. This family of molecules has been patented worldwide. The mission of SJT Molecular Research is to improve the quality of life for people. SJT Molecular's biggest success to date is the discovery of a family of molecules with a differential effect compared to current treatments, including a possible oral treatment as mono therapy.